[PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?]

Area of Science:

• Urology
• Oncology
• Medical Imaging

Context:

• Prostate-specific antigen (PSA) recurrence is a frequent challenge following curative therapy for localized prostate cancer.
• Distinguishing local recurrence from distant metastasis using current imaging modalities remains difficult.
• Salvage therapy decisions for PSA recurrence necessitate careful consideration of recurrence patterns and patient prognosis.

Purpose:

• To outline the diagnostic and therapeutic considerations for managing PSA recurrence after primary treatment for localized prostate cancer.
• To emphasize the importance of PSA kinetics and pathological criteria in guiding treatment decisions when imaging is inconclusive.
• To differentiate the need for histologic confirmation based on prior treatment modality (radical prostatectomy vs. radiation therapy).

Summary:

• PSA recurrence after initial prostate cancer treatment requires careful management to minimize metastatic spread.
• Treatment strategies should integrate PSA kinetics, pathological findings, and patient life expectancy, especially when imaging cannot differentiate local from distant recurrence.
• Histologic confirmation is advised for suspected local recurrence after radiation therapy but not typically required after radical prostatectomy before salvage therapy.

Impact:

• This guidance aids clinicians in optimizing treatment strategies for patients experiencing PSA recurrence, potentially improving outcomes.
• Improved understanding of PSA recurrence management can reduce the likelihood of disease progression to metastatic prostate cancer.
• Standardizing the approach to histologic confirmation based on prior therapy can streamline patient care and resource utilization.